Cargando…

Renal Function-Dependent Associations of Statins with Outcomes of Ischemic Stroke

Aim: Chronic kidney disease (CKD) is associated with unfavorable outcomes in patients with ischemic stroke. One major metabolic derangement of CKD is dyslipidemia, which can be managed by statins. This study aimed to investigate whether the association of statins with post-stroke outcomes would be a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Shin-Joe, Tang, Sung-Chun, Tsai, Li-Kai, Chen, Chih-Hung, Hsu, Shih-Pin, Sun, Yu, Lien, Li-Ming, Wei, Cheng-Yu, Lai, Ta-Chang, Chen, Po-Lin, Chen, Chien-Chung, Huang, Pai-Hao, Lin, Ching-Huang, Liu, Chung-Hsiang, Lin, Huey-Juan, Hu, Chaur-Jong, Lin, Cheng-Li, Jeng, Jiann-Shing, Hsu, Chung Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957032/
https://www.ncbi.nlm.nih.gov/pubmed/32418948
http://dx.doi.org/10.5551/jat.55210
Descripción
Sumario:Aim: Chronic kidney disease (CKD) is associated with unfavorable outcomes in patients with ischemic stroke. One major metabolic derangement of CKD is dyslipidemia, which can be managed by statins. This study aimed to investigate whether the association of statins with post-stroke outcomes would be affected by renal function. Methods: We evaluated the association of statin therapy at discharge with 3-month outcomes according to the estimated glomerular filtration rate (eGFR) of 50,092 patients with acute ischemic stroke from the Taiwan Stroke Registry from August 2006 to May 2016. The outcomes were mortality, functional outcome as modified Rankin Scale (mRS), and recurrent ischemic stroke at 3 months after index stroke. Results: Statin therapy at discharge was associated with lower risks of mortality (adjusted hazard ratio [aHR], 0.41; 95% confidence interval [CI], 0.34 to 0.50) and unfavorable functional outcomes (mRS 3–5; aHR, 0.80; 95% CI, 0.76 to 0.84) in ischemic stroke patients. After stratification by eGFR, the lower risk of mortality associated with statins was limited to patients with an eGFR above 15 mL/min/1.73 m(2). Using statins at discharge was correlated with a lower risk of unfavorable functional outcomes in patients with an eGFR of 60–89 mL/min/1.73 m(2). Statin therapy in patients with an eGFR of 60–89 mL/min/1.73 m(2) may be associated with a higher risk of recurrent ischemic stroke compared with nonusers (aHR, 1.29; 95% CI, 1.07 to 1.57). Conclusions: In patients with acute ischemic stroke, the associations of statins with mortality and functional outcomes was dependent on eGFR.